Earnings Call · Q1 FY2022·2022-05-12

Q1 22EPS -44.44%·Rev n/aQ4 21EPS -5.88%·Rev n/aQ3 21EPS -23.08%·Rev n/aQ2 21EPS -23.53%·Rev n/a⚠ consensus missing

Decoy Therapeutics Inc. SLRX

Daniel Kontoh-Boateng — Investor Relations or Corporate Communications

David Arthur — Director and Chief Executive Officer

Mark Rosenblum — Chief Financial Officer

−15.3%1d on move date−17.7% vs SPY3d−18.9%5d−11.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SLRX calls or request research access.

More SLRX calls Browse calls Request research access